Researchers have identified a novel genetic biomarker responsible for the progression of many breast and prostate cancers. The finding could bolster efforts to better identify patients who respond to certain types of chemotherapy drugs that attack the most aggressive forms of cancer. “Understanding and identifying biomarkers is a vital step toward cancer research and care,” said lead study author Michael Freeman from Cedars-Sinai Medical Centre in Los Angeles, California, US.